Photo by National Cancer Institute on Unsplash
A Cutting Edge Treatment for Cancer May Cause Rare, Secondary Cancers
November 30, 2023
A cutting-edge treatment for cancer may be linked to rare, secondary cancers.
The FDA is investigating an alarming finding on a promising cancer therapy invented at Penn Medicine, according to 6ABC-TV in Philadelphia. This therapy is being linked to rare, secondary cancers.
On Tuesday, the FDA announced that it had received “reports of T-cell malignancies or cancers, including a type of lymphoma, in people who received treatment with certain chimeric antigen receptor T-cell or CAR-T therapies,” according to CNN. They have received 19 reports of patients with adverse reactions to treatment.
The CAR-T treatment involves extracting disease-fighting T-cells from a patient, which are then re-engineered to fight cancer and put back in the body.
The statement from the FDA reads, “Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action.”
The agency’s announcement also said, “FDA has determined that the risk of T-cell malignancies applies to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies. T-cell malignancies have occurred in patients treated with several products in the class.”
Since 2017, the FDA has approved six commercial CAR-T cell therapies for blood cancers such as lymphomas and leukemias. Researchers are additionally testing these therapies for a variety of other cancers and autoimmune diseases.
Kymriah, the first CAR-T cell therapy, was considered a breakthrough when it was first approved. The FDA’s then commissioner, Scott Gottlieb, said at the time, “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer.”
The cost of Kymriah was a whopping $475,000. Many of today’s CAR-T cell therapies have similar costs.
As with any gene therapy product, the potential risk of developing secondary malignancies is labeled as a class warning in the U.S. prescribing information.
Recent News
Massive Data Breach Hits Ticketmaster, Affecting 560 Million Customers
Ticketmaster has fallen victim to a significant cyber-attack, potentially compromising the data of up to 560 million customers. The breach was confirmed by Ticketmaster’s parent company, Live Nation, which revealed that a notorious hacking group, ShinyHunters, is behind the attack. The hackers are demanding a ransom of approximately £400,000 to prevent the data from being sold on the dark web.
Toyota Recalls 100,000+ Tundra and Lexus LX SUVs Over Engine Debris Issue
Toyota has announced a recall for over 100,000 Tundra pickups and Lexus LX SUVs in North America due to potential engine issues caused by machining debris. This recall affects certain 2022-2023 models of the Tundra and LX, which are equipped with the new V6 twin-turbo engine. The V6 twin-turbo engine has faced considerable scrutiny regarding its reliability, especially when compared to the previous naturally aspirated V8 engines.
Wordle and Worldle Battle Over Names
A legal dispute has erupted between the wildly popular word game Wordle and the lesser-known geography game Worldle, centering on the similarity of their names. Wordle, which was developed by Josh Wardle in 2021 and later acquired by the New York Times in 2022 for a substantial sum, has gained immense popularity. In this game, players have six attempts to guess a five-letter word.
FDA Issues Recall for Crecelac Goat Milk Infant Formula
The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding Crecelac Goat Milk Infant Formula and other infant formula products imported and distributed by Dairy Manufacturers Inc. The alert highlights Cronobacter contamination concerns with Crecelac Infant Powdered Goat Milk Infant Formula. Although Dairy Manufacturers Inc. initiated a recall on May 24, 2024, due to non-compliance with FDA regulations, new findings of Cronobacter contamination have prompted further action.